Actively Recruiting
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Led by Takeda · Updated on 2026-02-20
100
Participants Needed
1
Research Sites
284 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.
CONDITIONS
Official Title
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with primary immunodeficiency (PID) enrolled in the PID patient registry
- Participants documented as having received the study drug in their treatment records
- Participants diagnosed with PID in the intractable disease information field
- Participants with recorded information on the presence or absence of adverse events
You will not qualify if you...
- Participants without recorded study drug use between January 24, 2024 and January 23, 2029
- Participants not diagnosed with PID in the intractable disease information field
- Participants without recorded information on adverse events
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Takeda selected site
Tokyo, Tokyo, Japan
Actively Recruiting
Research Team
T
Takeda Contact
CONTACT
S
Study Director
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here